Celgene Corp. (CELG)

90.69
0.00 (0.00)
NASDAQ : Health Technology
Prev Close 90.69
Open 90.18
Day Low/High 90.05 / 91.11
52 Wk Low/High 58.59 / 96.95
Volume 4.71M
Avg Volume 9.70M
Exchange NASDAQ
Shares Outstanding 700.24M
Market Cap 63.50B
EPS 5.70
P/E Ratio 23.02
Div & Yield N.A. (N.A)

Latest News

Celgene Downgraded to Hold at Jefferies

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

The Human Response Factor, Fed Moves, China Talks, MSFT Results: Market Recon

Many see the Fed as done for the year. Never assume. Read the words as they are written.

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

Jim Cramer: 7 Trends That Can Guide Us Through This Turmoil

These themes are working despite the turmoil in Washington and slowing global growth.

These 2 Biotech Stocks Seem Significantly Undervalued

These 2 Biotech Stocks Seem Significantly Undervalued

I would add to them on any significant dips in the market.

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

Real Money Post-Industrial Average Records 7% Gain So Far in 2019

The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Try This Allergan Two-Week Setup

Try This Allergan Two-Week Setup

The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.

Some Early 2019 Market Observations

Some Early 2019 Market Observations

I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

2 Small-Caps That Should Continue to Stage Comebacks in 2019

2 Small-Caps That Should Continue to Stage Comebacks in 2019

Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.

Real Money Post Industrial Average Outperformed the Market in 2018

Real Money Post Industrial Average Outperformed the Market in 2018

The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon

It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Jim Cramer: Best and Worst of the Dow in 2018

Jim Cramer: Best and Worst of the Dow in 2018

And which stocks are still a buy into 2019.

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang

Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.

Searching for Signs of Bottoming Action

Searching for Signs of Bottoming Action

The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

A Way to Exploit Algorithm-Induced Market Swings When Trading Biotech Issues

It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.

2 Small Biotech Stocks That Insiders Are Buying

2 Small Biotech Stocks That Insiders Are Buying

Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene Is Showing Us a Couple of Interesting Bullish Divergences

Celgene could be at a temporary low or it could be starting a new base pattern.

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

Jim Cramer: I Can't Believe How Badly Many Huge, Important Stocks Have Performed

I tire of hearing that there has been a correction.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.